Hansoh Pharmaceutical Group Company Limited Hansoh Pharmaceutical Group Company Limited

Hansoh Pharmaceutical Group Company Limited

3692

주식 순위 #916
Hansoh Pharmaceutical Group Company Limited, an investment holding company,... Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
주가
$4.36
시가총액
$26.43B
변동 (1일)
-0.87%
변동 (1년)
-5.62%
국가
CN
거래 Hansoh Pharmaceutical Group Company Limited (3692)

카테고리

Healthcare
Hansoh Pharmaceutical Group Company Limited (3692)의 주식 분할 이력
Hansoh Pharmaceutical Group Company Limited 주식 (심볼: 3692)은 총 0회의 주식 분할을 거쳤습니다.
가장 최근의 분할은 Oct 21, 2026에 발생했습니다.
Oct 21, 2026 이전에 매수한 3692 주식 1주는 현재 0주의 3692 주식에 해당합니다.
주식 분할 목록
연도 주식 분할 배수 누적 배수
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 주식 분할